Aliko Scientific signs strategic memorandum of understanding with Cellay Inc.

Paris, France – 11 May 2026 – 6:00 PM – Aliko Scientific SA (“Aliko Scientific” or the “Company”) (Euronext Growth Paris: ALIKO), an industrial and financial holding company focused on advanced oncology diagnostics, announces the signing of a strategic Memorandum of Understanding (“MoU”) with Cellay Inc., a U.S.-based company headquartered in Cambridge, Massachusetts and specialized in the development of Same Day OligoFISH® probes for chromosome enumeration applications.

The agreement marks the start of a synergistic commercial partnership focused on integrating the two companies’ complementary technologies into a single product offering for the urology segment. The aim is to accelerate the roll-out of a fully automated and highly efficient oncological diagnostic workflow in international markets, with a particular focus on the United States. The agreed commercial arrangement provides Ikonisys with royalties on the sale of Cellay reagents, confirming that the business model is increasingly shifting away from a one-off purchase towards a ‘pay-per-test’ model.

The partnership combines Aliko Scientific’s expertise across the entire diagnostic chain — through its subsidiaries Ikonisys Inc. and Hospitex International — with Cellay’s proprietary rapid hybridization probe technology. Together, the companies aim to provide laboratories and clinicians with an integrated solution spanning sample preparation, staining, scanning, AI-assisted analysis, and reporting.

Under the collaboration, Cellay will support the commercialization of Hospitex and Ikonisys solutions in the U.S. market, particularly within the urology diagnostics segment, while Aliko Scientific will distribute Cellay products internationally outside the United States. The parties will also cooperate on customer support, joint training programs, software optimization, and commercial development initiatives intended to enhance laboratory productivity and streamline diagnostic workflows.

Francesco Trisolini, CEO of Aliko Scientific, commented:
“This partnership represents a major strategic milestone for Aliko Scientific as we continue to expand our presence in the U.S. advanced diagnostics market. By combining the strengths of Ikonisys, Hospitex, and Cellay, we are creating a highly differentiated integrated diagnostic offering capable of delivering greater automation, faster turnaround times, and improved efficiency for laboratories.”

The Memorandum of Understanding establishes the initial framework for cooperation between the parties and may evolve into broader commercial and operational agreements in the future.

About ALIKO SCIENTIFIC (Ikonisys SA)

Headquartered in Paris, ALIKO SCIENTIFIC is the parent company of an international ecosystem of businesses dedicated to advancing oncology diagnostics. Listed on Euronext Growth Paris under the ticker ALIKO, the company coordinates industrial, financial and research activities through its subsidiaries: Ikonisys Inc. (USA) and Hospitex International (Italy). ALIKO SCIENTIFIC’s mission is to innovate cancer diagnosis by uniting cutting-edge technologies, resources, and strategic investments to create a global center of excellence in oncology.

For more information, visit: www.alikoscientific.com

About IKONISYS

Ikonisys is a global leader in automated diagnostics, specializing in fluorescence in situ hybridization (FISH) and circulating tumor cell (CTC) detection. Leveraging advanced artificial intelligence (AI) and a fully automated microscopy platform, Ikonisys provides unmatched precision, scalability, and efficiency in cancer diagnostics and treatment monitoring. Recognized as pioneer in automation for rare cell detection, Ikonisys is at the forefront of personalized medicine, empowering clinicians to deliver targeted therapies and improve patient outcomes.

For more information, visit: www.ikonisys.com

About HOSPITEX

Hospitex, based in Florence, Italy, is a global leader in cytology innovation. The company conducts in-house research, development, and production, thus ensuring the highest standards of quality. Hospitex offers the world’s most advanced Liquid-Based Cytology (LBC) technology, capable of processing any cytological sample with unmatched precision. Hospitex is uniquely positioned as the only company fully prepared for seamless digital integration, paving the way for a transformative future in cytology diagnostics.

For more information, visit: www.hospitex.com